Expanding the utility of cellular therapies to additional disease states as well as standardizing clinical management of patients treated with CAR-T cells and developing novel therapies to optimize clinical outcomes for patients with acute myeloid leukemia.
Retrovirus-based gene transfer into hematopoietic stem cells has emerged as a viable treatment for genetic, malignant and infectious diseases with the potential to significantly decrease global disease burden.
Clinical and research focus on improving outcome of hematopoietic cell transplantation (HCT). Allogeneic HCT has the potential to provide long-term survival and even cure in patients with hematological malignancies.
Laboratory studies are focused on preventing graft-versus-host-disease for children undergoing allogeneic stem cell transplants, the discovery of leukemia associated minor histocompatibility antigens and the development of adoptive T cell immunotherapy.
Infections in the immunocompromised host, especially diagnosis, prevention and treatment of CMV, VZV, BK virus, adenovirus, and respiratory virus infections. Research includes understanding the genetic basis of infeciton complications, genome and gene expression studies.
Research focus is on acute and chronic graft-vs.-host disease (GVHD), the amelioration of long-term complications associated with GVHD therapies, and the prevention of relapse after transplant in the context of continued immunosuppressive therapy.
Developing novel therapies and risk-stratification methods for adults with acute lymphoblastic leukemia. Radioimmunotherapy-based conditioning regimens for hematopoietic cell transplantation in adults with high-risk lymphoma.
Research is centered on 1) understanding the factors associated with successful adoptive transfer of immune T cells and improving the outcomes of both native and gene-modified T cells targeting viral and tumor antigens, 2) developing methods that improve the survival, proliferation and anti-tumor activity of infused T-cell products so as to better eliminate tumor targets and 3) clinical strategies to modulate the host immune environment as a means to optimally activate T cells in humans.
Pulmonologist and critical care specialist who sees patients with pulmonary complications after hematopoietic stem cell transplantation (HCT), including infectious pneumonia and non-infectious pulmonary complications.
Novel therapeutics in prostate and bladder cancer, correlative science/translational studies in clinical trials , clinical and molecular predictors of response to cancer therapies and circulating microRNA biomarkers for prostate cancer.
The Clurman Lab studies how cell division is regulated in normal cells, and how abnormal control of cell division leads to cancer. They hope to use these mechanistic insights into tumor formation to develop new cancer treatment strategies.
Focus is on colorectal, pancreas and liver cancers and other gastrointestinal malignancies. Research includes the assessment of genes affecting the progression of cancer, identifying new biomarkers, and the characterization of colorectal cancer Type X.
The primary focus of the Delaney Lab is the development and clinical translation of methodologies for the ex vivo expansion of hematopoietic stem and progenitor cells. In particular, we have focused on methods for the ex vivo expansion of cord blood stem and progenitor cells with the goal of improving outcomes for patients undergoing cord blood transplantation.
Clinical focus is diagnosis and management of benign and malignant hematologic disorders as well as solid tumors. Research includes developing immune-based approaches to prevent and treat relapse of myeloid cancers, including after allogeneic HSCT.
Determining how changes in microbial communities impact human health; identifying, characterizing, and culturing microbes found in the human genital tract; and associating the reproductive tract microbiome with human disease.
Developing molecular diagnostic tests to detect and identify pathogens in immunocompromised hosts such as cancer patients.
Hematopoietic cell transplantation for severe autoimmune diseases, nonmyeloablative hematopoietic cell transplantation, hematopoietic stem cell and T cell gene therapy and the development of radiation mitigators
The Geraghty laboratory is interested in the genetics of the immune response and the consequential functions of key components. We are examining the essential detail of the genetics and genomics of the immune response in humans and nonhuman primates, detail that differs among individuals and directly affects a plethora of immune interactions and derivative clinical outcomes.
Research is focused on the design and analysis of laboratory research, clinical trials and observational studies in hematopoietic cell transplant (HCT), and in rheumatology, breast cancer, ovarian cancer, as well as a wide variety of large laboratory projects at Fred Hutch and throughout the world.
Developing novel targeted therapies for lymphomas with particular emphasis on radioimmunotherapy-based transplant conditioning regimens, low toxicity proapoptotic agents for indolent lymphomas, and safe curative regimens for older adults with lymphoma.
Research is focused on the development, invasion and metastasis of intestinal cancers characterized by chromosome/genetic instability and dysregulated proliferation. Treats patients with cancers of the lung, rectum, small intestines or colon, as well as patients with myeloma and non-Hodgkin's lymphoma.
The Hockenbery lab studies programmed cell death (apoptosis) pathways that are defective in many cancer cells; and the role of cancer-cell metabolism in apoptosis, oncogene functions, and environmental/dietary risk factors, including excess supply of nutrients. After identifying cancer-selective targets, they carry out small-molecule screens for inhibitors to identify lead compounds as anticancer agents.
The initial focus was to study the role of inflammatory cell derived proteinases in diseases occurring within the lungs. To date, this has included novel findings for many disease processes including lung cancer, COPD/emphysema, acute lung injury, pulmonary infections, and pulmonary fibrosis. More recently, the focus has shifted to the tumor microenvironment.
Clinically important persistent and latent viral infections; curative therapies for latent viral infections ;diagnosis of disease caused by herpesviruses, enterovirus, JC and BK viruses, parvovirus B19, and hepatitis viruses
The Kiem Lab is focused on research and clinical trials using stem cell biology and stem cell gene transfer with the goal of developing stem cell-based treatment strategies for patients with genetic or infectious stem cells. We are conducting studies using embryonic stem cells and induced pluripotent stem cells.
Clinical expertise is hematology providing hematopoietic cell transplants to patients with blood disorders. Her research is focused on survivorship issues, quality-of-life and the impact of chronic graft-versus-host-disease.
Treats patients with sarcoma, a rare cancer of the bones and soft tissue, with a focus on GIST (gastrointestinal stromal tumor), intra-abdominal and retroperitoneal tumors and rare, aggressive forms of sarcoma.
Dr. Méndez’ focus is on head and neck cancers. He is a researcher and is an expert in the surgical treatment of head and neck cancers, including minimally invasive robotic surgery for tumors of the tongue and throat, microvascular reconstruction of the head and neck and thyroid cancers.
Research is focused on androgen and androgen receptor-related mechanisms of resistance that lead to prostate cancer progression. Current areas of research include pathways of intra-tumoral androgen steroidogenesis and metabolism, structural alterations in the androgen receptor, the activity of androgen transport proteins, and how alterations in these and other pathway may influence the sequencing of androgen and chemotherapy treatments. An important goal is to determine how patient and tumor-specific alterations in these proteins may be used to predict response to agents targeting these pathways.
Research focus is the understanding the molecular, cellular and physiological events that lead to cancer initiation and progression. A particular emphasis involves hormonal carcinogenesis and prostate cancer with the goal of developing new strategies for diagnosis, prognosis and therapy.
New ways to prevent and treat skin cancers
by studying the systems that control cell division. These systems help prevent cells with damaged DNA from reproducing and, when they malfunction, can affect cells’ chances of becoming cancerous.
Hematologic malignancies, including leukemias and lymphomas, and tailoring treatment plans to deliver high quality care. Developing radioimmunotherapies that use immune system proteins known as antibodies to selectively target radioactivity to cancer cells, sparing normal tissues.
Natural Killer Cell Receptor Diversity and CMV in Hematopoietic Cell Transplantation; Viral infections after Hematopoietic Stem Cell Transplantation; Epidemiology of invasive Fungal infections in Cord Blood Transplant Recipients and Clinical trials of the prevention of post-transplant infection
Studies focus on 1) understanding the roles of distinct T cell subsets in protective immunity to pathogens and tumors and on 2) the development and clinical application of adoptive T cell therapies for viral diseases and cancers, using unmodified and genetically modified antigen-specific T cells.
Studies the very first steps that lead to a productive immune response. These involve circulating “innate” immune cells that initially recognize problems, such as cells infected by a virus or transformed by malignant changes.
The overarching goal of the projects in the Simon laboratory is the development of small molecules as mechanistic probes for a variety of cellular processes and as potential lead compounds for the development of therapeutic agents. To this end we apply an interdisciplinary approach ranging from chemical synthesis and medicinal chemistry to genetics and cell biology. The compounds we are studying have been identified from large collections of synthetic, drug-like compounds and from natural sources. While screening compound libraries is a significant part of what we do the majority of our efforts go into mechanistic studies to understand the biology and pharmacology of lead compounds and efforts to improve their activity through chemical synthesis of analogs.
Stimulatory NKG2D lymphocyte receptor on natural killer (NK) cells and T cells, which interacts with multiple ligands that are selectably induced in viral infections, certain autoimmune diseases, and most notably in cancer
The Program in Transplantation Biology combines basic and translational research directed at understanding and eliminating major barriers to successful allogeneic hematopoietic stem cell transplantation; these include host-versus-graft reactions, graft failure, acute and chronic graft-versus-host disease (GVHD), regimen-related toxicities, and induction of graft-versus-tumor reactions. The program’s goal has been to use stem cell transplantation to treat patients with malignant and nonmalignant hematologic diseases.
Determining acute, long term and late complications of cancer treatment for hematopoietic cell transplantation and other cancer survivors, along with clinical trials to improve outcomes during and after cancer treatment
The Tapscott Lab studies gene transcription and expression in normal development and disease, with an additional emphasis on rhabdomysarcomas (cancers with characteristics of skeletal muscle) and human muscular dystrophies. Other research areas include gene and cell therapies for muscular dystrophy, and the biology of triplet repeats and their associated diseases.
Research is focused on increasing our knowledge of factors that increase the risk of idiopathic pneumonia syndrome (IPS) in transplant medicine, examining biomarkers from the lung of patients with IPS in effort to elucidate its biology and the role of blood component transfusions in lung injury
Research is focused on the the preclinical and early clinical development and characterization of novel antigen-directed immunotherapies for AML, the conduct of trials testing novel treatments and innovative care approaches for AML patients, and approaches to develop and improve diagnostic and prognostic tools in AML.
Clinical focus is treating patients with blood cancers such as leukemia, lymphoma, and multiple myeloma. Research is focused on cancer immunology, specifically the mechanisms and molecules that mediate graft-versus-host disease and graft-versus tumor.